{
  "id": "hcm_risk_scd",
  "title": "HCM Risk-SCD",
  "description": "Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.",
  "category": "cardiology",
  "version": "2014",
  "parameters": [
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Age at evaluation in years",
      "validation": {
        "min": 16,
        "max": 110
      },
      "unit": "years"
    },
    {
      "name": "family_history_scd",
      "type": "string",
      "required": true,
      "description": "History of sudden cardiac death in ≥1 first degree relatives <40 years of age or SCD in any relative with confirmed HCM at any age",
      "options": ["no", "yes"],
      "validation": {
        "enum": ["no", "yes"]
      },
      "unit": null
    },
    {
      "name": "max_wall_thickness",
      "type": "float",
      "required": true,
      "description": "Maximum wall thickness - greatest thickness in anterior septum, posterior septum, lateral wall, and posterior wall of the LV measured by echocardiography",
      "validation": {
        "min": 10,
        "max": 40
      },
      "unit": "mm"
    },
    {
      "name": "left_atrial_diameter",
      "type": "float",
      "required": true,
      "description": "Left atrial diameter determined by M-Mode or 2-D echocardiography in parasternal long axis view",
      "validation": {
        "min": 15,
        "max": 70
      },
      "unit": "mm"
    },
    {
      "name": "max_lvot_gradient",
      "type": "float",
      "required": true,
      "description": "Maximal left ventricular outflow tract gradient determined at rest and with Valsalva provocation (peak instantaneous gradient)",
      "validation": {
        "min": 0,
        "max": 200
      },
      "unit": "mmHg"
    },
    {
      "name": "nsvt",
      "type": "string",
      "required": true,
      "description": "Non-sustained ventricular tachycardia - ≥3 consecutive ventricular beats at a rate of ≥120 bpm and <30 s in duration on Holter monitoring",
      "options": ["no", "yes"],
      "validation": {
        "enum": ["no", "yes"]
      },
      "unit": null
    },
    {
      "name": "unexplained_syncope",
      "type": "string",
      "required": true,
      "description": "History of unexplained syncope at or prior to evaluation",
      "options": ["no", "yes"],
      "validation": {
        "enum": ["no", "yes"]
      },
      "unit": null
    }
  ],
  "result": {
    "name": "scd_risk",
    "type": "float",
    "unit": "%",
    "description": "5-year risk of sudden cardiac death"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0.0,
        "max": 3.999,
        "stage": "Low Risk",
        "description": "Low 5-year SCD risk",
        "interpretation": "ICD generally not indicated. Continue regular follow-up and reassess risk if clinical change occurs."
      },
      {
        "min": 4.0,
        "max": 5.999,
        "stage": "Intermediate Risk",
        "description": "Intermediate 5-year SCD risk",
        "interpretation": "ICD may be considered. Discuss risks and benefits with patient, consider additional risk modifiers."
      },
      {
        "min": 6.0,
        "max": 100.0,
        "stage": "High Risk",
        "description": "High 5-year SCD risk",
        "interpretation": "ICD should be considered. Strong recommendation for prophylactic ICD implantation after thorough discussion with patient."
      }
    ]
  },
  "references": [
    "O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439.",
    "Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.",
    "O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018 Mar 6;137(10):1015-1023."
  ],
  "formula": "Prognostic Index = 0.15939858*(Max wall thickness) - 0.00294271*(Max wall thickness)² + 0.0259082*(LA diameter) + 0.00446131*(Max LVOT gradient) + 0.4583082*(Family history SCD) + 0.82639195*(NSVT) + 0.71650361*(Unexplained syncope) - 0.01799934*(Age); 5-year SCD risk (%) = 1 - 0.998^exp(Prognostic Index)",
  "notes": [
    "For patients aged 16 years and older with HCM",
    "Not validated for use in pediatric patients (<16 years)",
    "Not for use in elite athletes",
    "Not for patients with metabolic diseases associated with HCM (e.g., Anderson-Fabry disease)",
    "Risk should be reassessed every 1-2 years or when clinical change occurs",
    "Additional risk modifiers may be considered in borderline cases"
  ]
}